Mylan delivers "one pill once a day" ARV in South Africa; Cipla Debuts first Enbrel biosimilar

USA-based generic drugmaker Mylan (Nasdaq: MYL) says that it has delivered, through its South African-based subsidiary Mylan (Proprietary) Limited), stock of the highly anticipated "one pill once a day" antiretroviral (ARV) combination to the South African National Department of Health's Gauteng depot. Mylan was selected in November 2012 to be one of the leading suppliers of ARV drugs to the National Department of Health for the tender period January 1, 2013 to December 31, 2014.

Last November, South African Minister of Health Aaron Motsoaledi announced that, as from
April 2013, “patients who are on ARV treatment will no longer have to take three tablets, but only need one tablet per day." On April 8 this year, Dr Motsoaledi launched the FDC ARVs at Phedisong 4 Community Health Clinic. "From June onwards, all other stable, non-complicated patients will be switched to FDCs after consultation with their clinicians," he explained.

To support the National Department of Health's commitment to providing this option to people living with HIV/AIDS in South Africa, Mylan has delivered stock ahead of the deadline. Additionally, as part of Mylan's efforts to further consumer education and support anti-counterfeit measures, Mylan has partnered with TrustaTAG Systems. TrustaTAG Systems developed PharmaTAG, a patented system using unique two-dimensional tags that enable consumers to use their mobile phones to simply scan the TAG on a product and gain access to patient-information leaflets, pack shots, company information and other items.